Trial Profile
The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Cefalexin (Primary) ; Ciprofloxacin (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 08 Mar 2012 Planned end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 08 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Sep 2005 New trial record.